Spectral Receives UKCA Authorization for Burn Indication Expected Commercialization 2nd Half 2024
- None.
- None.
The UKCA authorization of Spectral AI's DeepView AI®-Burn signifies a substantial advancement in the field of medical diagnostics. This technology leverages AI-enabled algorithms to analyze wounds, providing a 92% accuracy rate in predicting the necessity of surgical intervention. This is a marked improvement over the current standard that offers only 50% to 75% accuracy. The ability to expedite the treatment decision process has the potential to reduce hospitalization times and prevent the risk of infection associated with prolonged wound evaluation.
From a research perspective, the introduction of such a system could lead to a paradigm shift in wound care management, as it offers a more data-driven approach to diagnosis. This could also result in a reduction in healthcare costs due to decreased resource utilization and shorter patient stays. Moreover, the company's intention to extend the technology to pediatric care suggests a commitment to continuous innovation and expansion of its market reach.
The market potential for Spectral AI's DeepView AI®-Burn system in the UK and potentially other regions that recognize UKCA authorization is noteworthy. The company's ability to begin generating revenue in the second half of the year could positively impact its financial performance, contributing to the $28 million revenue guidance. The swift deployment of six devices for customer evaluation indicates a proactive approach to market penetration.
Furthermore, the expansion into markets that accept UKCA authorization, such as the Middle East, represents a strategic move to leverage regulatory synergies and broaden the product's commercial footprint. The medical diagnostics sector is highly competitive and Spectral AI's regulatory milestone could provide a competitive edge, enhancing investor confidence and potentially influencing the company's stock valuation.
From an economic standpoint, the UKCA authorization of the DeepView AI®-Burn system could lead to cost savings within the UK healthcare system. By reducing the evaluation period from weeks to seconds, the technology could minimize the economic burden of wound care on public health services. The efficiency gains and potential to lower the incidence of costly complications, such as infections, are pivotal in the context of a healthcare system that is increasingly pressured to optimize resource allocation.
The company's innovation aligns with the broader trend towards precision medicine and value-based healthcare, where treatments are tailored to individual patients to improve outcomes and reduce costs. The economic implications extend beyond immediate healthcare savings, potentially influencing broader health policy decisions and investment in AI-driven diagnostic tools.
DALLAS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that its predictive software DeepView AI®-Burn has obtained the final stage of UK Conformity Assessed (UKCA) authorization, for aiding in burn wound diagnosis in the United Kingdom.
"I am delighted to announce this achievement in our Company’s evolution. The completion of this milestone will allow us to sell our DeepView™ System in the UK and we expect to swiftly deploy six devices in the UK for customer evaluation and to begin generating revenue in the second half of this year.” said Wensheng Fan, the Company’s Chief Executive Officer. “In addition, this regulatory authorization opens up the ability to expand partnerships with regions such as the Middle East that recognize the UKCA authorization.” Revenue from commercialization in the UK in 2024 represents an addition to the
The DeepView® System wound imaging device uses AI-enabled algorithms analyzing real-life patient wounds that assess clinically validated data points to distinguish between healthy and damaged tissue within seconds, unlike the current standard of care, which requires up to three to four weeks of evaluation. The technology establishes a high level of accuracy,
“The current practice of prolonged and expensive observation with open wounds that risk infection before deciding on the best management of care is outdated,” said Prof. Paul Chadwick, Spectral AI’s Executive Vice President of the Company’s United Kingdom subsidiary. “This protracted decision process burdens the patient as well as the healthcare system with unnecessary hospitalization time. The authorization of the DeepView System could effectively obviate the need for these long observation periods, accelerating the way we manage burn wounds in the UK.”
UKCA marking is a certification system established by the UK government to ensure that products meet specified standards for sale in the UK (England, Wales, and Scotland). The DeepView AI®-Burn is currently indicated for individuals aged eighteen and above. The Company aims to extend its technology to benefit pediatric populations and is continuing to initiate case studies and case series with surgeons at leading burn centers.
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. DeepView is a predictive device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, DeepView is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView, visit www.spectral-ai.com.
Forward Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
Contacts:
Investors:
The Equity Group
Devin Sullivan
Managing Director
dsullivan@equityny.com
Conor Rodriguez
Analyst
crodriguez@equityny.com
Media:
Russo Partners
David Schull
Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com
FAQ
What is the significance of the UKCA authorization for Spectral AI, Inc. (MDAI)?
What revenue impact is expected from the UK commercialization in 2024 for Spectral AI, Inc. (MDAI)?
What accuracy level does the DeepView AI®-Burn technology achieve in distinguishing healthy and damaged tissue?
Who is the Chief Executive Officer of Spectral AI, Inc. (MDAI)?
What is the purpose of the DeepView AI®-Burn technology?
